^
    13d
    SCALET: Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov)
    P1/2, N=49, Recruiting, National Health Research Institutes, Taiwan | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    Cabometyx (cabozantinib tablet) • lanreotide prolonged-release subcutaneous
    14d
    ALXN2420-Acro-201: Phase 2 Study of ALXN2420 versus Placebo in Combination with Somatostatin Analogs in Participants with Acromegaly (2025-521243-20-00)
    P1/2, N=32, Suspended, Alexion Pharmaceuticals Inc. | Recruiting --> Suspended
    Trial suspension
    |
    IGF1 (Insulin-like growth factor 1)
    |
    lanreotide prolonged-release subcutaneous
    2ms
    LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, Antonio Fojo | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    lanreotide prolonged-release subcutaneous
    2ms
    ALXN2420-Acro-201: Phase 2 Study of ALXN2420 versus Placebo in Combination with Somatostatin Analogs in Participants with Acromegaly (2025-521243-20-00)
    P1/2, N=32, Recruiting, Alexion Pharmaceuticals Inc.
    New P1/2 trial
    |
    IGF1 (Insulin-like growth factor 1)
    |
    lanreotide prolonged-release subcutaneous
    6ms
    SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (clinicaltrials.gov)
    P3, N=332, Active, not recruiting, Camurus AB | Trial completion date: Dec 2027 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    lanreotide prolonged-release subcutaneous • Oclaiz (octreotide subcutaneous depot) • octreotide acetate
    8ms
    Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula (clinicaltrials.gov)
    P3, N=274, Recruiting, SWOG Cancer Research Network | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lanreotide prolonged-release subcutaneous • Somatuline LA (lanreotide suspension intramuscular)
    9ms
    The Combination Therapy of Pasireotide LAR Plus Pegvisomant and Cabergoline Relieved Acromegaly-Related Headache in a Female Patient with AIP-Mutated Acromegaly: A Case Report. (PubMed, Endocr Metab Immune Disord Drug Targets)
    This case report highlights the potential benefits of pasireotide in the treatment of refractory headaches, particularly when combined with pegvisomant.  .
    Journal
    |
    SSTR (Somatostatin Receptor) • IGF1 (Insulin-like growth factor 1)
    |
    lanreotide prolonged-release subcutaneous • Signifor LAR (pasireotide long acting release)
    10ms
    RIALTO: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (clinicaltrials.gov)
    P3, N=166, Recruiting, Grupo Espanol de Tumores Neuroendocrinos | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lutathera (lutetium Lu 177 dotatate) • lanreotide prolonged-release subcutaneous • octreotide acetate
    12ms
    Heterozygous Men1(+/T) Knockout Mice Do Not Develop Bronchopulmonary Neuroendocrine Hyperplasia or Neoplasia but Bronchial Adenocarcinoma. (PubMed, Adv Respir Med)
    Heterozygous Men1(+/T) knockout mice do not develop bronchopulmonary NEN or precursor lesions, but pulmonary adenocarcinoma. This surprising result needs to be investigated in more detail.
    Preclinical • Journal
    |
    SYP (Synaptophysin)
    |
    lanreotide prolonged-release subcutaneous
    1year
    RIALTO: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (clinicaltrials.gov)
    P3, N=166, Not yet recruiting, Grupo Espanol de Tumores Neuroendocrinos
    New P3 trial
    |
    Lutathera (lutetium Lu 177 dotatate) • lanreotide prolonged-release subcutaneous • octreotide acetate
    1year
    LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, Antonio Fojo | Recruiting --> Active, not recruiting | N=40 --> 10 | Trial completion date: Dec 2023 --> Mar 2026 | Trial primary completion date: Dec 2023 --> Mar 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    lanreotide prolonged-release subcutaneous
    1year
    Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET). (PubMed, J Neuroendocrinol)
    We conclude that immune checkpoint blockade had low activity in unselected patients with grade 1 and 2 GEP-NETs. Further study of strategies to reduce Treg activation or enhance effector memory activation during immunotherapy is warranted.
    P1/2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • lanreotide prolonged-release subcutaneous